Why the study?
Does cilnidipine effectively reduce blood pressure and provide organ protection in individuals with mild to moderate essential hypertension?
Does cilnidipine effectively reduce blood pressure and provide organ protection in individuals with mild to moderate essential hypertension?
Cilnidipine is an effective and well-tolerated treatment for mild to moderate essential hypertension, offering organ protection and a favorable side effect profile compared to traditional L-type CCBs.
Answers are grounded in this paper and cite their sources.
Cilnidipine's dual N/L-type blockade may aid hypertension control; leaves open outcome superiority versus other CCBs.
Calcium channel blockers (CCBs) are widely used antihypertensive agents due to their effectiveness in reducing blood pressure (BP), along with their good tolerability and evidence of reducing hypertension (HTN)-related cardiovascular and renal diseases. Cilnidipine, a unique dihydropyridine calcium antagonist, exhibits potent inhibitory action on both N-type and L-type voltage-dependent calcium channels. With excellent oral absorption and a prolonged duration of action, it demonstrates a significant antihypertensive effect. It effectively reduces BP both systolic and diastolic while providing renal, neurological, and cardiovascular protection. Unlike L-type CCBs, cilnidipine does not increase pulse rates (PRs) and is associated with reduced occurrence of pedal edema. Cilnidipine is an effective treatment choice for individuals with mild to moderate essential HTN, whether it is administered alone or in conjunction with other treatment modalities.
No takes yet. Share an insight, caveat, or question.
Tiwaskar et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: